



**THREE GATEWAY CENTER**  
100 Mulberry Street, 15<sup>th</sup> Floor  
Newark, NJ 07102  
T: 973.757.1100  
F: 973.757.1090  
**WALSH.LAW**

Liza M. Walsh  
Direct Dial: (973) 757-1101  
[lwalsh@walsh.law](mailto:lwalsh@walsh.law)

March 11, 2024

**VIA ECF**

Hon. Michael A. Hammer, U.S.M.J.  
United States District Court for the District of New Jersey  
Martin Luther King Jr. Bldg. & U.S. Courthouse  
50 Walnut Street  
Newark, New Jersey 07102

Re: ***Teva Branded Pharmaceutical Products R&D, Inc., et al. v. Amneal  
Pharmaceuticals of New York, LLC, et al.***  
**Civil Action No. 2:23-cv-20964 (SRC-MAH)**

Dear Judge Hammer:

This firm, together with Goodwin Procter LLP, represents Plaintiffs Teva Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., and Teva Pharmaceuticals USA, Inc. (collectively, "Teva") in connection with the above-referenced matter.

We write jointly on behalf of the parties to request a modification to the briefing schedule for the pending motions (D.E. 45) in light of the recent application by the Federal Trade Commission for permission to file a motion seeking leave to file an amicus brief on March 22, 2024 (D.E. 51). Under this revised schedule, Teva's consolidated opposition papers to Amneal's motion and reply brief to Teva's motion would be filed on April 15, 2024 and Amneal's reply brief to Amneal's motion would be filed on April 30, 2024.

Should the Court find the above request acceptable, the parties request that Your Honor "So Order" this letter. As always, we thank the Court for its attention to this matter and are available should Your Honor or Your Honor's staff have any questions.

Respectfully submitted,

*s/ Liza M. Walsh*

Liza M. Walsh

cc: All Counsel of Record (via ECF and Email)

SO ORDERED:  
**SO ORDERED**

Hon. ~~Michael A. Hammer~~  
**Michael A. Hammer, U.S.M.J.**

Date: 3/12/24